期刊
EUROPEAN JOURNAL OF NANOMEDICINE
卷 4, 期 2-4, 页码 89-93出版社
WALTER DE GRUYTER GMBH
DOI: 10.1515/ejnm-2012-0010
关键词
active targeting; antibody; immunoliposomes; nanoparticles; targeting ligand
资金
- Ontario Institute for Cancer Research Intellectual Property Development and Commercialization Fund
- Canadian Institutes of Health Research operating grant [MOP-119471]
- proof-of-principal [PPP122898]
- MaRS Innovation and Ontario Centres of Excellence proofof- principal grant
- National Cancer Institute Nanotechnology Characterization Award
- Prostate Cancer Foundation
- Ontario Ministry of Economic Development and Innovation
The active targeting approach has been widely employed to improve nanoparticle drug delivery. Contrary to popular conceptions, attachment of a targeting ligand to a nanopaticle does not alter its biodistribution, but only increases its internalization by target cells. Despite its potential, this strategy has drawbacks that can negate efficacy against tumors. Specifically, compared to non-targeted nanoparticles, a number of active targeting nanoparticles have decreased blood circulation time due to non-specific binding or immunogenicity, reduced tumor penetration, and high susceptibility to lysosomal degradation after internalization. In order to maximize the advantages and overcome the disadvantages, the active targeting approach is best suited for delivering membrane impermeable drugs to targets directly exposed to i.v. injected nanoparticles, such as those in circulation or in the luminal site of tumor vasculatures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据